Back to search results

68Ga-FAPI-46 PET/CT for Crohn's Disease Fibrosis

This study is looking at whether a special imaging scan, called a PET/CT, using a substance called 68Ga-FAPI-46, can find areas of scarring (fibrosis) in the small bowel of people with Crohn's disease. The goal is to see if this scan can detect early signs of scarring, even before strictures (narrowing of the bowel) fully develop. You might be able to join if you are over 18, have small bowel Crohn's disease, and have had a recent MRI or CT scan of your intestines. The study will consider it a success if all participants complete the PET/CT scan with 68Ga-FAPI-46. The current status of this study is unclear, and it plans to enroll 45 participants.

Study design
This is a prospective, case-control study that will compare participants with and without small bowel strictures. It aims to enroll 45 participants.
What's involved
You would undergo a 68Ga-FAPI-46 PET/CT scan. The study completion is expected to average 2 years.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed through study completion, which is an average of 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07273188

68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease

Recruiting
EARLY_PHASE1Ages 18+InterventionalDiagnostic
Mayo Clinic
~45 participants
Updated 2026-02-09 on ClinicalTrials.gov
What's tested:Ga68-FAPI-46

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Completion of PET/CT with Ga68-FAPI-46 by all participants
Measured over Through study completion, an average of 2 years
+1 more outcome measured

Conditions

Crohn's Disease
Intestinal Fibrosis
Inflamatory Bowel Disease
Intestinal Strictures Related to Crohn´s Disease

Explore related trials

Crohn Disease

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • David J Bartlett · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Brian Will
[email protected]
507-266-0111
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Known small bowel Crohn's disease
Research or clinical MR enterography, or clinical CT enterography, within 3 months.
Male or female with age greater than 18 years old.
Diagnosis of Crohn's disease by a gastroenterologist
Willingness to undergo 68Ga-FAPI-46 PET/CT
Subjects with the capacity to give informed consent and willingness to provide written consent

Exclusion

Pregnant and/or breast-feeding subjects.
Hypersensitivity to any excipients in 68Ga-FAPI-46

What this trial measures

  • Completion of PET/CT with Ga68-FAPI-46 by all participantsThrough study completion, an average of 2 years
  • Number of participants completing PET/CT with Ga68-FAPI-46Through study completion, an average of 2 years

    Participants complete PET/CT with Ga68-FAPI-46